Últimas noticias sobre ResMed (NYSE:RMD) Bolsa

ResMed

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

ResMed Inc

Remedy Entertainment PLC

Richmond Minerals Inc

RICHMOND MINERALS INC by Richmond Minerals Inc.

In the current market session, ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) stock price is at $249.21, after a 2.68% decrease. However, over the past month, the company's stock increased by 4.38%, and in the past year, by 76.47%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1730137516_0.png" alt="Past Year Chart" />

<h3>ResMed P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
ResMed has a lower P/E than the aggregate P/E of 263.82 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730137516_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

P/E Ratio Insights for ResMed

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Sector Perform and raises the price target from $224 to $232.

Price Target

Analyst Ratings

RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $232

Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week&#8217;s pivotal earnings releases from <a href="https://www.benzinga.com/topic/magnificent-7">five of the &#8220;Magnificent Seven&#8221; stocks.</a>
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) will all report quarterly earnings between Oct. 29 and Oct. 31.
Combined, nearly 45% of the S&amp;P 500 by market cap is set to report results next week, with other heavyweights including McDonald&#8217;s Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>).
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) continued its upward trajectory on Friday, rising 2.7% following a massive 21% jump on Thursday — its biggest one-day gain since May 2013.
The S&amp;P 500 was up 0.5% at midday trading in New York, while the Nasdaq 100 surged by 1.5%, fueled by semiconductor stocks. 
The Dow Jones Industrial Average fell 0.3%, on track to end a six-week winning streak. The U.S. dollar strengthened further, with the DXY Index rising past the 104 mark, setting up for a fourth straight week of gains. Meanwhile, Treasury yields were steady. 
WTI crude rose 1.8%, driven by concerns over geopolitical tensions in the Middle East. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is up slightly at $67,695.
<h1 class="wp-block-heading">Friday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,500.56</td>
<td>1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,839.28</td>
<td>0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,219.60</td>
<td>0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,271.11</td>
<td>-0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:50 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent102225&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.5% to $582.19.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;eased 0.2% to $423.18.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.3% to $498.83.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.2% up to $220.09.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up by 1.4%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.9%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
<ul>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) rallied 7% to levels last seen in October 2021 on better-than-expected quarterly results. </li>
<li>Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) rallied over 10% after reporting record new lease bookings. </li>
</ul>
Other stocks reacting to earnings included:
<ul>
<li>Ameriprise Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>), down 0.13%</li>
<li>DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), down 1%</li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) up 7.6%, </li>
<li>Skechers U.S.A. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) down 0.2%, </li>
<li>Western Digital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) up 7.6%, </li>
<li>Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>), up 11%</li>
<li>Edward Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), down by 0.6%</li>
<li>HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), down 10%, </li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), up 6%, </li>
<li>Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), down 3.4%, </li>
<li>Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), up 6.7%, </li>
<li>Saia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>), up 9.2%. </li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41549147/goldman-sachs-analyst-remains-bullish-on-boeing-despite-weak-q3-long-term-deep-valu">Goldman Sachs Analyst Remains Bullish On Boeing Despite Weak Q3: &#8216;Long-Term Deep-Value Opportunity</a>&#8216;</li>
</ul>
Photo: Shutterstock

Earnings

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

AAPL

AMZN

DECK

SPDR Dow Jones Industrial Average ETF Trust

DXCM

GOOG

GOOGL

MSFT

RIVN

SAIA

TSLA

Select Sector SPDR-Consumer Discretionary

Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Overweight and raises the price target from $251 to $266.

Keybanc Maintains Overweight on ResMed, Raises Price Target to $266

On Thursday, ResMed Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.04</a>.
The company reported sales of $1.224 billion, up 11%, beating the consensus of $1.18 billion, driven by increased demand for sleep devices and masks portfolio and strong growth across the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41529733/resmed-inc-announces-results-for-the-first-quarter-of-fiscal-year-2025" rel="noreferrer noopener">Residential Care Software business</a>.
Residential Care Software revenue increased by 12% on a constant currency basis, reflecting continued organic growth in the Residential Care Software portfolio.
Gross margin increased by 420 basis points mainly due to manufacturing efficiencies, component cost improvements, and an increase in average selling prices. Non-GAAP&nbsp;gross margin increased by 320 basis.
&#8220;Our first-quarter fiscal year 2025 results reflect ongoing momentum and strong execution across all areas of our business,&#8221; said Mick Farrell, Chairman and CEO of ResMed. &#8220;We delivered 11% year-over-year revenue growth, and our focus on operational excellence resulted in another quarter of year-over-year margin expansion and a 34% increase in operating profit.&#8221;
Adjusted operating income increased 27% to $406.4 million. Adjusted net income increased by 35% to $325 million.
William Blair notes that ResMed&#8217;s revenue and earnings per share surpassed expectations, with EPS exceeding their estimates by $0.16 (an 8% beat). The analyst <a target="_blank" href="https://www.benzinga.com/quote/RMD/analyst-ratings" rel="noreferrer noopener">rates the stock Outperform.</a>
The company&#8217;s strong execution, leading market position, and balanced emphasis on growth and profitability reinforce the analyst&#8217;s confidence in ResMed&#8217;s solid fundamentals and positive outlook.
Following another quarter of robust core performance and the release of its five-year strategic and financial outlook, William Blair sees ResMed well-positioned to capitalize on enduring sleep health trends.
While concerns surrounding GLP-1 therapies may re-emerge as investors assess upcoming developments, including potential label expansions, ResMed&#8217;s strong revenue and earnings growth are expected to sustain momentum, as seen in recent quarters.
&#8220;With catalysts to come from margin expansion, new product launches, and the recent resolution to the competitive consent decree, we believe the fundamentals in this durable medtech growth story remain positive,&#8221; William Blair analyst writes.
Price Action: RMD stock is up 7.81% at $257.71 at last check Friday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41545501/trouble-for-us-airlines-china-demand-slump-boeing-strike-global-carriers-shifting-focus" target="_blank" rel="noreferrer noopener">Trouble For US Airlines: China Demand Slump, Boeing Strike, Global Carriers Shifting Focus</a></li>
</ul>

Analyst Color

Large Cap

Health Care

Reiteration

Movers

Trading Ideas

General

Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst

ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $240.67, a high estimate of $283.00, and a low estimate of $180.00. Surpassing the previous average price target of $234.00, the current average has increased by 2.85%.
<img src="https://www.benzinga.com/files/images/story/2024/1729868492_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive ResMed. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$283.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Craig Wong-Pan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$224.00</td>
<td>$206.00</td>
</tr>
<tr>
<td>Lyanne Harrison</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$280.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Underperform</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$236.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Wong-Pan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$206.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$251.00</td>
<td>$238.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$236.00</td>
<td>$236.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ResMed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of ResMed compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for ResMed's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into ResMed's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RMD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ResMed analyst ratings.</a>
<h2>All You Need to Know About ResMed</h2>
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
<h3>ResMed: Financial Performance Dissected</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining ResMed's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.01% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ResMed's net margin is impressive, surpassing industry averages. With a net margin of 23.89%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): ResMed's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.16% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.27%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.18.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For ResMed

Baird analyst Joe Vruwink maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Outperform and raises the price target from $280 to $283.

Baird Maintains Outperform on ResMed, Raises Price Target to $283

WIIM

ResMed shares are trading higher after the company reported better-than-expected Q1 financial results.

CORRECTION: ResMed Ticker Is RMD

Needham analyst Mike Matson reiterates ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Hold.

Needham Reiterates Hold on ResMed

ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) reported quarterly earnings of $2.20 per share which beat the analyst consensus estimate of $2.04 by 7.84 percent. The company reported quarterly sales of $1.224 billion which beat the analyst consensus estimate of $1.180 billion by 3.75 percent. This is a 11.12 percent increase over sales of $1.102 billion the same period last year.

Earnings Beats

ResMed Q1 2025 Adj. EPS $2.20 Beats $2.04 Estimate, Sales $1.224B Beat $1.180B Estimate

ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) is set to give its latest quarterly earnings report on Thursday, 2024-10-24. Here's what investors need to know before the announcement.
Analysts estimate that ResMed will report an earnings per share (EPS) of $2.04. 
ResMed bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 4.23% increase in the share price the next day.
Here's a look at ResMed's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.06</td>
<td>1.91</td>
<td>1.79</td>
<td>1.62</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.08</td>
<td>2.13</td>
<td>1.88</td>
<td>1.64</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>19.0%</td>
<td>8.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729699328_0.png" alt="eps graph" />
<h3>Market Performance of ResMed's Stock</h3>
Shares of ResMed were trading at $239.98 as of October 22. Over the last 52-week period, shares are up 70.56%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analysts' Perspectives on ResMed</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on ResMed.
Analysts have given ResMed a total of 8 ratings, with the consensus rating being Neutral. The average one-year price target is $235.38, indicating a potential 1.92% downside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of IDEXX Laboratories, DexCom and GE HealthCare Techs, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for IDEXX Laboratories, with an average 1-year price target of $543.75, suggesting a potential 126.58% upside.</li>
<li>DexCom received a Outperform consensus from analysts, with an average 1-year price target of $97.44, implying a potential 59.4% downside.</li>
<li>GE HealthCare Techs received a Buy consensus from analysts, with an average 1-year price target of $94.67, implying a potential 60.55% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary presents essential metrics for IDEXX Laboratories, DexCom and GE HealthCare Techs, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ResMed</td>
<td>Neutral</td>
<td>9.01%</td>
<td>$715.53M</td>
<td>6.16%</td>
</tr>
<tr>
<td>IDEXX Laboratories</td>
<td>Neutral</td>
<td>6.35%</td>
<td>$619.16M</td>
<td>12.91%</td>
</tr>
<tr>
<td>DexCom</td>
<td>Outperform</td>
<td>15.26%</td>
<td>$626.70M</td>
<td>6.13%</td>
</tr>
<tr>
<td>GE HealthCare Techs</td>
<td>Buy</td>
<td>0.46%</td>
<td>$2.00B</td>
<td>5.63%</td>
</tr>
</tbody>
</table>

Key Takeaway:
ResMed ranks in the top for Revenue Growth among its peers. It is in the middle for Gross Profit and Return on Equity.
<h3>Delving into ResMed's Background</h3>
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
<h3>A Deep Dive into ResMed's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, ResMed showcased positive performance, achieving a revenue growth rate of 9.01% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: ResMed's net margin is impressive, surpassing industry averages. With a net margin of 23.89%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): ResMed's ROE excels beyond industry benchmarks, reaching 6.16%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ResMed's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.27% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: ResMed's debt-to-equity ratio is below the industry average. With a ratio of 0.18, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/RMD/earnings">To track all earnings releases for ResMed visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at ResMed's Future Earnings

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Sector Perform and raises the price target from $206 to $224.

RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $224

New Five-Year Financial Outlook ResMed's new five-year financial outlook includes:
<ul>
<li>High-single-digit revenue growth</li>
<li>Earnings growth higher than revenue growth</li>
</ul>
"Since our last Investor Day in 2021, we have delivered on our commitments, and this new outlook reinforces that ResMed is well positioned to maintain its track record of strong financial performance," said Brett Sandercock, Chief Financial Officer of ResMed. "Our financial strength and low capital requirements create robust cash generation, and our capital allocation strategy will continue to prioritize innovation – through reinvestment in our core business, a disciplined and strategic approach to M&amp;A, and a balanced capital return policy. We are confident this approach will deliver significant value to shareholders as we execute our 2030 Strategy."
2030 Strategy ResMed will achieve its new financial goals through the execution of its clear and focused 2030 Strategy across three pillars to drive growth:
<ol>
<li>Grow and differentiate ResMed's unmatched core sleep apnea franchise, led by demand generation and demand capture: The 2030 Strategy is underpinned by a focus on ResMed's sleep apnea core, where ResMed is the leader in making smaller, quieter, more comfortable and more connected products that people love – all working together in a more intelligent ecosystem. ResMed will continue differentiating its technology with AI/ML to drive enhanced therapy performance, consumer appeal, and user experience. New commercial excellence and demand generation initiatives will drive more patients into ResMed's funnel, where they will be served by a robust roadmap of new products, such as the AirTouch N30i next-generation CPAP mask unveiled earlier today. &nbsp;</li>
<li>Capitalize on ResMed's market opportunity and brand advantage in broader sleep health and breathing health adjacencies: ResMed's evolution is designed to capitalize on key macro trends, including the enhanced spotlight on sleep apnea due to pharmaceuticals and consumer tech. Additionally, ResMed's strong brand and expertise in sleep health position the Company to address the large, untapped sleep health market opportunity, including 860 million people who suffer from insomnia and 480 million people who suffer from COPD.</li>
<li>Invest 7% of revenue into R&amp;D to invent, create, and differentiate a fully integrated digital ecosystem for health technology delivered at home: With a large installed base of more than 28 million patients in its AirView&#x2122; platform – and more than 8.3 million patients registered to the myAir&#x2122; platform – ResMed seamlessly integrates devices and data to enhance provider efficiency and enable more personalized care. As ResMed's 2030 Strategy initiatives drive more patients to its funnel, the ecosystem will further build its data advantage. ResMed's leading residential care software solutions are a key enabler of its core sleep and breathing health business. They drive substantial revenue synergies, contribute to core demand generation, and provide cohesion and interoperability for ResMed's AI-driven digital platform.</li>
</ol>
Implemented in 2023, ResMed's 2030 Operating Model reorganized the company to ensure it remains product-led, customer-centric, and brand-enhanced. The 2030 Operating Model further accelerates ResMed's ability to reach consumers where they are, achieve the five-year financial outlook, and unlock value.

Guidance

ResMed Unveils 2030 Strategy To Drive Growth, Profitability, And Shareholder Returns; New 5-Year Outlook Includes High-Single-Digit Revenue Growth; Earnings Growth Higher Than Revenue Growth

<a href="https://www.globenewswire.com/Tracker?data=jer_jok7qlySMfsyxxA8D0ehdqJLO1vR_-G4UBNMu4BQzZyoF5g6ef018npugG9OKvsSfJJRDi71KVm6mBO5zw==">ResMed</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>, ASX: RMD)))), the world's leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ResMed first in CPAP (continuous positive airway pressure) mask innovation with the launch of the <a href="https://www.globenewswire.com/Tracker?data=vZ8QC91YrRA3qQpiuraELW5mhAtqdLcQAjKw-GEimmzCiY2eA7cApLWQJD0kiSTh9XgKr03qoqq7BiFGyw_WpzbJqY-z00tMlwouwkzvrrgKIv6jt64q9qsTVJ37cqYE">AirTouch&#x2122; N30i</a>. Designed to create a natural and comfortable sleep experience for users, the AirTouch N30i is a fabric-wrapped frame featuring a soft, breathable, and moisture-wicking design for optimal comfort in a tube-up design. &nbsp;
Sleep apnea affects more than 54 million people in the United States and nearly one billion people worldwide1. This chronic sleep-related breathing disorder can impair daily functioning and significantly increase the risk of serious comorbidities such as hypertension, diabetes, cardiovascular disease, and stroke2.

Biotech

ResMed Enhances CPAP Therapy With Its First Fabric Mask, Designed To Make It Easier For People To Embrace Their Treatment And Improve Overall Sleep Health

B of A Securities analyst Lyanne Harrison maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Buy and raises the price target from $240 to $270.

B of A Securities Maintains Buy on ResMed, Raises Price Target to $270

In the preceding three months, 7 analysts have released ratings for ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated ResMed and provided 12-month price targets. The average target is $227.57, accompanied by a high estimate of $280.00 and a low estimate of $180.00. Witnessing a positive shift, the current average has risen by 3.68% from the previous average price target of $219.50.
<img src="https://www.benzinga.com/files/images/story/2024/1727182881_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of ResMed by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$280.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Underperform</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$236.00</td>
<td>-</td>
</tr>
<tr>
<td>Craig Wong-Pan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$206.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$251.00</td>
<td>$238.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$236.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Craig Wong-Pan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$204.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ResMed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ResMed compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of ResMed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of ResMed's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RMD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ResMed analyst ratings.</a>
<h2>Discovering ResMed: A Closer Look</h2>
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
<h3>ResMed: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: ResMed displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 9.01%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: ResMed's net margin excels beyond industry benchmarks, reaching 23.89%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): ResMed's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.16% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): ResMed's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.27% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: ResMed's debt-to-equity ratio is below the industry average. With a ratio of 0.18, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: ResMed Through The Eyes Of 7 Analysts

Baird analyst Joe Vruwink initiates coverage on ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Outperform rating and announces Price Target of $280.

Initiation

Baird Initiates Coverage On ResMed with Outperform Rating, Announces Price Target of $280

Bank of America Securities analyst Lyanne Harrison maintained a Buy rating on Resmed (RMD – Research Report) today. The company's shares opened tod...

Bank of America Securities Reaffirms Their Buy Rating on Resmed (RMD)

KeyBanc raised the firm's price target on ResMed (RMD) to $266 from $251 and keeps an Overweight rating on the shares following the Q1 earnings rep...

ResMed price target raised to $266 from $251 at KeyBanc

In a report released yesterday, David Low from J.P. Morgan maintained a Buy rating on Resmed (RMD – Research Report), with a price target of $270.0...

J.P. Morgan Sticks to Its Buy Rating for Resmed (RMD)

In a report released yesterday, David Low from J.P. Morgan maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs p...

J.P. Morgan Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)

In a report released today, Derek Jellinek from Morgans maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ...

Morgans Remains a Buy on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)

Wilsons analyst Shane Storey maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research Repo...

Wilsons Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)

Dividend Champion, Contender, And Challenger Highlights: Week Of November 3

My Top 15 High-Growth Dividend Stocks For November 2024

Top 50 High-Quality Dividend Growth Stocks - October 2024 Results

Baird Q3 2024 Mid Cap Growth Equity Fund Commentary

AAON

ABBV

ALLE

AMAT

AMCR

APOG

APTV

BROS

BWXT

CASY

CBAN

CGNX

CHCT

CIVB

COIN

CRAI

CSGP

CSWI

CTAS

CWEN

DLTR

EBTC

EFSI

EPAM

FANG

FAST

FBIZ

FBMS

FCBC

FELE

FIVE

FSBW

GABC

GRMN

HBCP

HESM

HFWA

IBCP

ICLR

INTU

JBHT

JKHY

KLAC

KNSL

LECO

LKFN

LRCX

LSCC

MAIN

MANH

MATX

MCHP

MKTX

MPLX

MPWR

MSCI

NDSN

NIDB

NTES

NXPI

NXRT

ODFL

ORRF

PAYX

PODD

POOL

QCOM

RACE

RGEN

ROST

SBFG

SBUX

SCHD

SIRI

SRCE

STBA

TECH

TREX

TSCO

TXNM

UMBF

VEEV

WDFN

WTFC

ZION

Press Releases

Vaping Expected to Increase COPD Health and Economic Burden by 2050

ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock Exchange

Travel

ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health

ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health

ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns

ResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 2024

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025

Legal

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of ResMed Inc. (NYSE:RMD) and Encourages Investors to Contact the Firm

ResMed Announces Participation in the UBS Global Healthcare Conference

Small Cap

Opinion

Exploring the $188 Billion Opportunity: Why AI is Set to Transform Global Healthcare by 2030

AVAI

CLOV

HWAIF

Comments

ResMed

Noticias

Últimas noticias sobre ResMed (NYSE:RMD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL